Document And Entity Information |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Document Information Line Items | |
| Entity Central Index Key | 0001783036 |
| Document Type | POS AM |
| Entity Registrant Name | NewcelX Ltd. |
| Entity Incorporation, State or Country Code | V8 |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Amendment Description | This Post-Effective Amendment No. 2 (“Amendment No. 2”) to the Registration Statement on Form F-4 (File No. 333-284075) of NewcelX Ltd., as successor to NLS Pharmaceutics Ltd., (the “Registration Statement”) is being filed solely for the purposes of (i) including language provided by Rule 473(b) of the Securities Act of 1933 for the automatic effectiveness of the Registration Statement 20 days following the filing of Amendment No. 2, (ii) updating the name of the registrant and (iii) filing updated Exhibits 23.2, 23.4 and 24.1 and in connection therewith to amend and restate the exhibit index set forth in Part II of the Registration Statement. This Amendment No. 2 does not modify any provision of the prospectus that forms a part of the Registration Statement. Accordingly, a preliminary prospectus has been omitted. |
| Amendment Flag | true |